ADCs are designed to deliver chemotherapy directly to tumours. However, more than 95% of the dose often ends up in healthy tissues, decreasing efficacy and increasing toxicity.
The recent acquisition of ImmunoGen by AbbVie, which followed the earlier acquisition of Seagen by Pfizer, has brought renewed attention to antibody-drug conjugates (ADCs), highlighting the
Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of invest
Food group Orion Group has taken a 25% in South Korean biotech LegoChem Bioscience, becoming its largest shareholder, as part of a push into the biotech sector.